Epilepsy is a neurological disorder characterized by abnormal brain activity, causing seizures or unusual behaviors or sensations. Even though anyone can develop epilepsy, children and older adults are slightly more susceptible.

Medical treatment helps in ~70% of cases and often requires therapeutic drug monitoring. Therapeutic drug monitoring requires blood sampling and frequent visits to healthcare providers. Drug concentrations in blood often do not correlate with improved clinical outcome and minimal side effects.

Metabolization of medication is highly specific to individuals. This is especially critical for medications with a narrow therapeutic range. Valproic acid (VPA) is such a medication and is the treatment of choice for generalized or difficult to classify epilepsy.

We at DBI support research activities to advance therapeutic drug monitoring with state-of-the-art breath analysis in epilepsy. Our certified DBI-EPIbreath^® test only needs an exhale to estimate the drug concentration of VPA in blood and the risks of severe side effects and seizures. Thus, it is ideally suited to support healthcare providers in their treatment decisions in epilepsy.